IONS Ionis Pharmaceuticals Inc.

+1.6  (+2%)
Previous Close 67.48
Open 67.71
Price To Book 7.65
Market Cap 9,705,760,586
Shares 140,500,298
Volume 626,393
Short Ratio
Av. Daily Volume 1,075,572

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiation announced October 13, 2017.
Alzheimer's disease
Phase 2b data due 1H 2020.
Rare hyperlipidemias
Phase 2b data due 1H 2020.
Hyperlipoproteinemia and established cardiovascular disease
First patient enrolled in Phase 3 trial announced January 28, 2019.
Huntington's Disease
Phase 3 trial to be initiated 2H 2019.
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 interim data released November 2016.
Cardiovascular disease
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2b data likely due 2019.
End-stage renal disease
CRL issued August 27, 2018.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
Type 2 diabetes
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
Type 2 diabetes
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
Inotersen (IONIS-TTRRx)
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.
Phase 3 data due 2021.
Amyotrophic lateral sclerosis (ALS)
Phase 2 trial to be initiated early 2019.
Geographic Atrophy (GA)
Phase 1b/2 data likely due 2019.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer
Phase 1/2 data and Phase 3 trial initiation due 2H 2019.
hATTR Amyloidosis
Phase 2 data likely due 2019.
Hepatitis B virus (HBV)
Phase 2 data likely due 2019.

Latest News

  1. Ionis Pharmaceuticals, Inc. (IONS) Q2 2019 Earnings Call Transcript
  2. Ionis Pharmaceuticals Looks to Partners to Pay the Bills
  3. Market Takes Off After Tariffs Pushed Back
  4. Edited Transcript of IONS earnings conference call or presentation 7-Aug-19 3:30pm GMT
  5. 3 Charts That Suggest Now Is the Time to Buy Into Biotech
  6. New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome
  7. Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates
  8. The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout
  9. Ionis Reports Second Quarter 2019 Financial Results
  10. Akcea Reports Financial Results and Highlights for Second Quarter 2019
  11. Akcea and Ionis Report Top-line Results from the BROADEN Study with WAYLIVRA® (volanesorsen) in Patients with Familial Partial Lipodystrophy
  12. Does Ionis Pharmaceuticals (NASDAQ:IONS) Have A Healthy Balance Sheet?
  13. Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for
  14. Rate Cut Wait Almost Over
  15. Ionis Pharmaceuticals to hold second quarter 2019 financial results webcast
  16. Ionis Pharmaceuticals Inc (IONS) Chairman & CEO Stanley T Crooke Sold $702,500 of Shares
  17. Ionis Pharmaceuticals IONS- 2019 Top Picks' Mid-Year Update
  18. Late Surge Helps S&P Join NASDAQ in the Green
  19. Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients